Acrux (ACR.AX) Stock Price
Acrux Price
Over the last 19 years Acrux grew revenue by 2.6% annually, reaching 4.53 M AUD. Earnings per share have declined at 19.5% per year over the last 6 years. For Acrux, the net margin of -131.3% is up versus -263.5% a few years ago. At today's price the dividend yield works out to roughly 7.79%. The payout ratio is around 2% of earnings. The dividend has grown at 7.4% per year over the past 5 years. The stock trades about 22% above its 52-week low.
Acrux stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Acrux over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Acrux stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Acrux's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Acrux Price |
|---|---|
| 9/2/2026 | 0.01 AUD |
| 9/1/2026 | 0.01 AUD |
| 8/31/2026 | 0.01 AUD |
| 8/28/2026 | 0.01 AUD |
| 8/27/2026 | 0.01 AUD |
| 8/26/2026 | 0.01 AUD |
| 8/25/2026 | 0.01 AUD |
| 8/24/2026 | 0.01 AUD |
| 8/21/2026 | 0.01 AUD |
| 8/20/2026 | 0.01 AUD |
| 8/19/2026 | 0.01 AUD |
| 8/18/2026 | 0.01 AUD |
| 8/17/2026 | 0.01 AUD |
| 8/14/2026 | 0.01 AUD |
| 8/13/2026 | 0.01 AUD |
| 8/12/2026 | 0.01 AUD |
| 8/11/2026 | 0.01 AUD |
| 8/10/2026 | 0.01 AUD |
| 8/7/2026 | 0.01 AUD |
| 8/6/2026 | 0.01 AUD |
| 8/5/2026 | 0.01 AUD |
| 8/4/2026 | 0.01 AUD |
| 8/3/2026 | 0.01 AUD |
| 7/31/2026 | 0.01 AUD |
| 7/30/2026 | 0.01 AUD |
| 7/29/2026 | 0.01 AUD |
| 7/28/2026 | 0.01 AUD |
| 7/27/2026 | 0.01 AUD |
| 7/24/2026 | 0.01 AUD |
| 7/23/2026 | 0.01 AUD |
Acrux Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Acrux Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM AUD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM AUD |
| EBITM AUD |
| EBIT MARGIN% |
| NET INCOMEM AUD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.AUD |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.00 | 16.00 | 53.00 | 25.00 | 28.00 | 23.00 | 3.00 | 5.00 | 3.00 | 4.00 | 5.00 | 11.00 | 8.00 | 4.00 | 20.00 | 15.00 |
| -89.25 | 60.00 | 231.25 | -52.83 | 12.00 | -17.86 | -86.96 | 66.67 | -40.00 | 33.33 | 25.00 | 120.00 | -27.27 | -50.00 | 400.00 | -25.00 |
| 100.00 | 100.00 | 98.11 | 96.00 | 96.43 | 100.00 | 100.00 | 100.00 | 133.33 | 100.00 | 80.00 | 100.00 | 50.00 | 100.00 | 100.00 | 100.00 |
| 10.00 | 16.00 | 52.00 | 24.00 | 27.00 | 23.00 | 3.00 | 5.00 | 4.00 | 4.00 | 4.00 | 11.00 | 4.00 | 4.00 | 20.00 | 15.00 |
| 4.00 | 9.00 | 45.00 | 16.00 | 18.00 | 11.00 | -10.00 | -8.00 | -9.00 | -12.00 | -9.00 | – | -5.00 | -5.00 | 10.00 | 5.00 |
| 40.00 | 56.25 | 84.91 | 64.00 | 64.29 | 47.83 | -333.33 | -160.00 | -300.00 | -300.00 | -180.00 | – | -62.50 | -125.00 | 50.00 | 33.33 |
| 7.00 | 6.00 | 27.00 | 11.00 | 12.00 | – | -14.00 | -8.00 | -9.00 | -12.00 | -9.00 | – | -5.00 | -5.00 | 12.00 | 6.00 |
| -87.72 | -14.29 | 350.00 | -59.26 | 9.09 | – | – | -42.86 | 12.50 | 33.33 | -25.00 | – | – | – | -340.00 | -50.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 166.51 | 166.51 | 166.52 | 166.52 | 166.52 | 166.52 | 166.52 | 166.58 | 167.77 | 219.73 | 283.88 | 286.46 | 289.50 | 352.16 | 352.16 | 352.16 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Acrux generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Acrux retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Acrux's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Acrux has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Acrux's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Acrux stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Acrux Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Acrux business model & stock analysis
Acrux SWOT Analysis
Strengths
Acrux Ltd possesses several strengths that contribute to its success in the market:
- Strong brand reputation in the industry
- Robust and innovative product portfolio
- Well-established distribution network
- Experienced and skilled workforce
- Efficient operational processes
Despite its strengths, Acrux Ltd also faces certain weaknesses that need to be addressed:
- Dependence on key suppliers
- Limited international market presence
- Relatively high production costs
- Inadequate online presence compared to competitors
- Lack of diversification in product range
Acrux Ltd can capitalize on the following opportunities to expand its market share:
- Emerging untapped markets with high growth potential
- Increasing demand for eco-friendly and sustainable products
- Partnerships and collaborations with other industry leaders
- Advancements in technology for product development
- Expansion into online retail channels
Acrux Ltd should be cautious of the following threats in the market:
- Intense competition from existing and new players
- Economic downturn and fluctuations in market conditions
- Changing consumer preferences and trends
- Potential disruptions in supply chain
- Regulatory changes impacting the industry
Weaknesses
Despite its strengths, Acrux Ltd also faces certain weaknesses that need to be addressed:
- Dependence on key suppliers
- Limited international market presence
- Relatively high production costs
- Inadequate online presence compared to competitors
- Lack of diversification in product range
Acrux Ltd can capitalize on the following opportunities to expand its market share:
- Emerging untapped markets with high growth potential
- Increasing demand for eco-friendly and sustainable products
- Partnerships and collaborations with other industry leaders
- Advancements in technology for product development
- Expansion into online retail channels
Acrux Ltd should be cautious of the following threats in the market:
- Intense competition from existing and new players
- Economic downturn and fluctuations in market conditions
- Changing consumer preferences and trends
- Potential disruptions in supply chain
- Regulatory changes impacting the industry
Opportunities
Acrux Ltd can capitalize on the following opportunities to expand its market share:
- Emerging untapped markets with high growth potential
- Increasing demand for eco-friendly and sustainable products
- Partnerships and collaborations with other industry leaders
- Advancements in technology for product development
- Expansion into online retail channels
Acrux Ltd should be cautious of the following threats in the market:
- Intense competition from existing and new players
- Economic downturn and fluctuations in market conditions
- Changing consumer preferences and trends
- Potential disruptions in supply chain
- Regulatory changes impacting the industry
Threats
Acrux Ltd should be cautious of the following threats in the market:
- Intense competition from existing and new players
- Economic downturn and fluctuations in market conditions
- Changing consumer preferences and trends
- Potential disruptions in supply chain
- Regulatory changes impacting the industry
Acrux Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Acrux historical P/E ratio, EBIT multiple, and P/S ratio
Acrux annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Acrux shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Acrux Dividend History
6 years of dividend payments
Acrux dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
EESG©
Eulerpool ESG Scorecard© for the Acrux stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Acrux shareholder structure
| % | Name |
|---|---|
2.09444% | |
1.65286% | |
1.06911% | |
0.56112% |
Acrux Executives and Management Board
8 members · 25 % women
Mr. Michael Kotsanis
Chief Executive Officer, Managing Director, Executive Director · since 2014
701,959.00 AUD
Management
Ms. Joanna Johnson
Chief Financial Officer, Company Secretary
Board of Directors
Ms. Felicia Colagrande
Product Development and Technical Affairs Director
Mr. Mark Hyman
Project and Technical Development Director
Mr. Ross Dobinson
Independent Non-Executive Chairman of the Board · since 1998
Dr. Geoffrey Brooke
Independent Non-Executive Director
Dr. Timothy Oldham
Independent Non-Executive Director
Mr. Donald Brumley
Independent Non-Executive Director
Acrux Supply Chain
Acrux Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.39 | 0.80 | 0.59 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.68 | 0.55 | -0.66 | ||
| 2 | 0.67 | 0.89 | 0.27 |
Frequently asked questions about Acrux
The business model of Acrux Ltd is focused on pharmaceutical research and development, specifically in the area of innovative transdermal drug delivery. Through its proprietary technology, Acrux has developed unique skin delivery solutions that enable the efficient delivery of a wide range of medications. With a strong emphasis on research and collaboration, Acrux aims to partner with pharmaceutical companies to develop and commercialize new transdermal products. This approach allows Acrux to generate revenue through licensing agreements and royalties, leveraging its expertise in the development and delivery of innovative drug treatments.
Acrux Ltd is primarily active in the pharmaceutical industry.
The main competitors of Acrux Ltd in the market are companies like Johnson & Johnson, Novartis AG, and GlaxoSmithKline Plc. These pharmaceutical giants also specialize in developing and marketing medical products, including topical dermatological treatments. As a renowned stock in the industry, Acrux Ltd faces stiff competition from these key players in the market.
Acrux Ltd is an Australian pharmaceutical company that specializes in developing and commercializing innovative dermatology products. Established in 1998, Acrux has grown to become a recognized leader in the transdermal drug delivery market. The company has achieved significant milestones, such as launching their first product, Axiron, in collaboration with global partners. Acrux's research and development efforts focus on creating effective treatments for various skin conditions and disorders. With a strong emphasis on innovation and quality, Acrux continues to strive for breakthrough advancements in the pharmaceutical industry.
Acrux Ltd has achieved several significant milestones throughout its history. Some notable achievements include the successful development and commercialization of innovative pharmaceutical products, collaborations with reputable partners, and regulatory approvals of key medications. The company's dedication to research and development has led to breakthroughs in dermatology, resulting in the launch of pioneering solutions for various skin conditions. Acrux Ltd's commitment to enhancing patient care and well-being truly sets them apart in the healthcare sector. Through their continuous efforts, Acrux Ltd has firmly established itself as a leading player in the pharmaceutical industry, consistently delivering impactful solutions to meet evolving market needs.
Acrux Ltd primarily operates in Australia, focusing on the development, manufacture, and commercialization of pharmaceutical products. With its headquarters located in West Melbourne, Acrux Ltd primarily serves the domestic market, catering to the healthcare needs of Australian consumers. The company's presence in Australia allows it to benefit from the country's robust healthcare sector and regulatory environment. By specializing in innovative and patient-friendly drug delivery technologies, Acrux Ltd aims to enhance treatment options for various medical conditions, demonstrating its commitment to improving healthcare outcomes for Australians.
Acrux Ltd is a renowned company that embodies a strong set of values and a robust corporate philosophy. By providing innovative solutions and exceptional products, Acrux Ltd aims to improve the lives of its customers. The company's commitment to excellence and customer satisfaction is evident in its continuous strive for quality and reliability. With a focus on research, development, and continuous improvement, Acrux Ltd maintains a leadership position in the industry. The company's values of integrity, transparency, and accountability underpin its business operations and foster long-lasting relationships with stakeholders. Acrux Ltd's corporate philosophy emphasizes sustainability, social responsibility, and ethical business practices, enabling it to make a positive impact in the industry and the wider community.
5 analysts currently rate the Acrux stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Acrux to generate revenue of 20.34 M AUD and earnings per share of 0.04 AUD.
Converted at the current exchange rate, the Acrux share trades at 0.01 EUR (0.01 AUD).
The Acrux share (ACR.AX) is listed on 3 stock exchanges, including: Frankfurt (FJY.F), ASX (ACR.AX).
The company Acrux Ltd is an Australian company specializing in the development of pharmaceutical products. Acrux's business model includes various divisions, including research and development of new drugs, manufacturing and marketing of existing products, and licensing of technologies. One of Acrux's most well-known products is Axiron, a testosterone preparation in the form of a deodorant used to treat hypogonadism in men. Axiron is sold in over 35 countries worldwide and is one of the leading testosterone preparations on the market. Another important product of Acrux is Evamist, an estradiol spray used to treat menopausal symptoms in women. Evamist is also distributed worldwide and is known for its ease of use and effectiveness. Acrux pursues an open innovation strategy and collaborates with other companies to develop new technologies and products. For example, the company has an agreement with Poxel SA to develop a new diabetes medication. In addition, Acrux has a wide portfolio of technologies and know-how in the field of topical drug delivery. The company licenses these technologies and also works with other companies to incorporate them into new products. However, the pharmaceutical industry is highly competitive, which means that Acrux must regularly develop new products to remain competitive. For this reason, the company invests heavily in research and development and leverages its experience in topical administration to develop new products that meet the medical needs of patients. In summary, Acrux’s business model is focused on developing high-quality pharmaceutical products supported by innovative technologies and partnerships with other companies. Through investment in research and development and close collaboration with partners and customers, Acrux is able to develop innovative solutions and strengthen its position in the competitive market.
The expected revenue of Acrux is 20.34 M AUD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Acrux is 12.77 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Acrux is currently 0.30. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Acrux stock.
The price-to-sales ratio (P/S) of Acrux is currently 0.19. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Acrux stock.
The Eulerpool Quality Score for Acrux is 1/10.
The ISIN of Acrux is AU000000ACR3. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Acrux is A0B8LR. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Acrux is ACR.AX. The ticker symbol is used to trade Acrux shares on the stock exchange.
Over the past 12 months, Acrux paid a dividend of 0.00 AUD . This corresponds to a dividend yield of about 7.79 %. For the coming 12 months, Acrux is expected to pay a dividend of 0.00 AUD.
The current dividend yield of Acrux is 7.79 %.
Acrux pays a dividend, distributed in the months of , , , .
Acrux paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0.00 AUD are expected. This corresponds to a dividend yield of 15.58 %.
Acrux is assigned to the 'Health' sector.
To receive the latest dividend of Acrux from amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
The dividends of Acrux are distributed in AUD.
Acrux stock
Acrux Peer Group
Acrux Ticker
Acrux FIGI
All fundamentals and in-depth analysis of Acrux
Our stock analysis for Acrux stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acrux. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.